ad

AD 0261 is a radical scavenger. It has a strong inhibitory action on the generation of lipid peroxides and superoxide anions.

AD-2646 has antidepressant activity and inhibits 2-deoxy-D-glucose (2-DG)-induced gastric acid secretion.

AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.

AD1058 is a potent and selective ATR inhibitor (IC50 = 1.6 nM) that crosses the blood-brain barrier with significant in vivo anticancer activity. It is commonly used in the study of brain metastasis and CNS metastasis by inhibiting cell proliferation, disrupting the cell cycle and inducing apoptosis.

AD57, as polypharmacological cancer therapeutic, is designed to regulate multiple targets related to cancer blocks the receptor tyrosine kinase RET in Drosophila (IC50: 2 nM). AD57 effectively suppresses tyrosine kinase RET, weakens the activity of numero

AD 11 is a bioactive chemical.

AD 128 is a bioactive chemical and therapeutic agent.

AD 1308 is a bioactive chemical.

AD 2239 is a bioactive chemical.

AD 5 is a bioactive chemical.

AD 8717 has a wide range of applications in life science related research.

AD-1491 is a bioactive chemical.

AD5075 is a bioactive chemical.

Multitarget AD inhibitor-1 is a reversible and selective inhibitor of butyrylcholinesterase (BuChE) with IC50 values of 7.22 μM for human BuChE (hBuChE) and 1.55 μM for equine serum BuChE (eqBuChE). It also exhibits inhibitory activity towards β-secretase (IC50 41.60 μM), amyloid β aggregation (IC50 3.09 μM), and tau aggregation. As a diphenylpropylamine derivative, Multitarget AD inhibitor-1 is promising for research into multifunctional, disease-modifying treatments for Alzheimer's disease.

AD80, a multikinase inhibitor, targets RET, RAF, SRC, and S6K with significantly reduced activity on mTOR.

AD2765, also known as AD 2845 and Sphingosylphosphoryl choline, is a novel thiourea derivative of sphingomyelin that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death.

AD-35 is a neuroprotectant for treating Alzheimer's diseases by significantly inhibiting the production and release of proinflammatory cytokines TNF-α and IL-1β.

FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration a

N-Trifluoroacetyladriamycin is a metabolite of Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar). Valrubicin is a chemotherapy drug utilized to treat bladder cancer. Valrubicin is the anthracycline doxorubicin analog and is administ

AD-67 is a biochemical reagent that can be used as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery.

Bermoprofen (AD-1590) is an orally active non-steroidal anti-inflammatory compound with analgesic properties, utilized in gastric ulcer studies.

Galanthamine hydrobromide (Galantamine hydrobromide), a long-acting and centrally active AChE inhibitor (IC50:410 nM), is an allosteric potentiator at neuronal nicotinic ACh receptors.

Pioglitazone hydrochloride (AD 4833) is the hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.

Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate.